Investing.com - POINT Biopharma Global (NASDAQ: PNT) reported third quarter EPS of $-0.314, $0.01 worse than the analyst estimate of $-0.302. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
POINT Biopharma Global's stock price closed at $13.120. It is up 52.030% in the last 3 months and up 43.540% in the last 12 months.
POINT Biopharma Global saw 2 positive EPS revisions and 7 negative EPS revisions in the last 90 days. See POINT Biopharma Global's stock price’s past reactions to earnings here.
According to InvestingPro, POINT Biopharma Global's Financial Health score is "excellent performance".
Check out POINT Biopharma Global's recent earnings performance, and POINT Biopharma Global's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar